Weight Loss News and Research

Latest Weight Loss News and Research

A new tool that predicts obesity-related disease risk beyond BMI

OBSCORE is a data-driven tool that identifies high-risk individuals for obesity-related diseases, enhancing treatment targeting beyond traditional BMI metrics.

5 May 2026

Study highlights stigma surrounding popular GLP-1 weight loss drugs

Glucagonlike peptide-1 (GLP-1) medications have taken over the national conversation around weight loss.

4 May 2026

Child health experts launch GenHEART to tackle Australia's obesity crisis

Heart health, diet, exercise and sleep will be targeted under a multi-pronged strategy by child health experts to address Australia's obesity crisis.

4 May 2026

Semaglutide as a promising new treatment for alcohol use disorder

Research indicates semaglutide can significantly decrease alcohol consumption and cravings in individuals with comorbid obesity and alcohol use disorder.

4 May 2026

Five-target drug beats GLP-1/GIP therapy in obese diabetic mice

A Nature study reports a single-molecule GLP-1–GIP–lanifibranor quintuple agonist that targets incretin receptor-expressing cells while activating PPARα/γ/δ pathways. In obese and insulin-resistant mice, the compound reduced body weight, food intake, and hyperglycaemia more effectively than semaglutide or GLP-1R–GIPR co-agonism, while remaining a preclinical finding.

30 Apr 2026

New screening tool predicts health risks for people living with obesity

A simple tool, developed by researchers at Queen Mary University of London and the Berlin Institute of Health at Charité, could help identify which people living with obesity or overweight are most likely to develop serious obesity-related conditions such as type 2 diabetes and heart disease.

30 Apr 2026

New research shows weight loss is possible without GLP-1

Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.

30 Apr 2026

AI model detects pancreatic cancer years before clinical diagnosis

An AI model (REDMOD) can pick up the very early subtle tissue changes of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, which conventional imaging and the human eye find difficult to detect, finds research published online in the journal Gut.

28 Apr 2026

Study finds season of entry impacts childhood obesity outcomes

Childhood obesity remains a major health challenge, and effective interventions often depend on more than nutritional advice or exercise plans alone.

28 Apr 2026

Obesity may leave immune cells stuck in inflammatory mode after weight loss

A new EMBO Reports study suggests that obesity can leave a lasting epigenetic imprint on CD4 T cells, delaying the restoration of adaptive immune balance after weight loss. Using mouse models and human cohorts, researchers linked this immune “memory” to DNA methylation changes, saturated fatty acids, autophagy, and immune senescence.

28 Apr 2026

GLP-1 drugs promise wider health benefits, but experts urge caution on use

GLP-1 receptor agonists are reshaping care for type 2 diabetes, obesity, chronic kidney disease, and obstructive sleep apnea, with evidence for glycemic, weight-loss, cardiovascular, and renal benefits. The review urges nurse practitioners to balance expanding clinical promise with careful prescribing, patient education, monitoring, access advocacy, and vigilance for gastrointestinal, endocrine, pregnancy-related, and rare serious risks.

27 Apr 2026

GLP-1 weight loss is driven mainly by fat loss, not muscle loss

GLP-1-based therapies helped adults with overweight or obesity lose weight mainly by reducing fat mass and visceral adipose tissue, while lean body mass losses were generally modest. The findings suggest these treatments can support higher-quality weight loss when paired with individualized care, nutrition, and resistance training.

27 Apr 2026

Obesity leaves lasting molecular tags on the immune system

People who live with obesity are 'tagging' a memory of being overweight on a key part of the immune system - leaving people with ongoing risk of obesity-related conditions years after losing weight, according to a 10 year-long study published in EMBO Reports.

27 Apr 2026

Yoga to help manage obesity-related heart and metabolic risks

The impact of yoga on heart health in obesity is modest, suggesting it as a complementary approach for improving metabolic outcomes in high BMI populations.

27 Apr 2026

Losing weight improves heart muscle contraction in people with obesity and heart failure

In a new research report, a team of scientists led by Johns Hopkins Medicine say people with severe obesity and a common type of heart failure experience weakened heart muscles, and that losing weight may reverse some of these effects.

25 Apr 2026

People judge weight loss more harshly when GLP-1 drugs are involved, study finds

In four pre-registered studies across Belgium, the US, and the UK, people judged anti-obesity medication users as putting in less effort and, in turn, viewed them as less moral, competent, warm, and deserving than non-users. The findings suggest that effort moralization may help drive stigma around GLP-1-based weight-loss treatment, even when medication is used alongside diet and exercise.

23 Apr 2026

Endoscopic procedure may prevent weight regain after GLP-1 discontinuation

An outpatient procedure may offer a way for the estimated 70% of people who discontinue popular weight-loss drugs to avoid regaining the pounds they shed, according to a study to be presented at Digestive Disease Week (DDW) 2026.

23 Apr 2026

Tirzepatide significantly reduces cardiovascular risk in high-risk patients

Two new studies show that tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (RA), significantly reduces cardiovascular risk in high-risk patients, including those undergoing percutaneous coronary intervention (PCI) and those with obesity undergoing transcatheter aortic valve replacement (TAVR).

23 Apr 2026

Experimental drug kills aggressive breast cancer by toxic fat buildup

An experimental drug targeting triple-negative breast cancer overwhelms cancer cells with toxic fats, according to new tests on human-derived tumors in mice.

22 Apr 2026

Tirzepatide vs. semaglutide: Study compares cost and health outcomes in obesity

In a US societal-perspective lifetime simulation based on SURMOUNT-5 data, tirzepatide was projected to deliver lower total costs and better health outcomes than semaglutide for adults with obesity or overweight without type 2 diabetes.

22 Apr 2026